pharma · Hyperphagia · Bariatric Surgery · AARD
Ark Therapeutics
Arkana Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker AARD. Primary therapeutic focus areas include Hyperphagia, Bariatric Surgery, Obesity, Prader-Willi Syndrome, Aut
Boulder, USA HQ
2025 Founded
4 Employees
Public company Type
AARD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2025
- Employees
- 4
- Programs
- 6
- Drugs
- 5
- Patents
- 7
Placebo
Phase 3 · small molecule · Hyperphagia
Placebo for Hyperphagia is a Phase 3 program (small_molecule) at Ark Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code AVK-101-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ark Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Hyperphagia
- Status
- on_hold
- Trials
- 1